Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Cameron Green, MSc info@remapcap.org


Svenja Peters, MSc EU.remapcap@umcutrecht.nl


Study Location:

Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Medical Conditions

COVID-19
Pneumonia


This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia.

The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia.

In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19.

REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19 in the United States of America.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Apr 2016 Feb 2026

Publications

"REMAP-CAP Writing Committee for the REMAP-CAP Investigators; Bradbury CA, Lawler PR, Stanworth SJ, McVerry BJ, McQuilten Z, Higgins AM, Mouncey PR, Al-Beidh F, Rowan KM, Berry LR, Lorenzi E, Zarychanski R, Arabi YM, Annane D, Beane A, van Bentum-Puijk W, Bhimani Z, Bihari S, Bonten MJM, Brunkhorst FM, Buzgau A, Buxton M, Carrier M, Cheng AC, Cove M, Detry MA, Estcourt LJ, Fitzgerald M, Girard TD, Goligher EC, Goossens H, Haniffa R, Hills T, Huang DT, Horvat CM, Hunt BJ, Ichihara N, Lamontagne F, Leavis HL, Linstrum KM, Litton E, Marshall JC, McAuley DF, McGlothlin A, McGuinness SP, Middeldorp S, Montgomery SK, Morpeth SC, Murthy S, Neal MD, Nichol AD, Parke RL, Parker JC, Reyes LF, Saito H, Santos MS, Saunders CT, Serpa-Neto A, Seymour CW, Shankar-Hari M, Singh V, Tolppa T, Turgeon AF, Turner AM, van de Veerdonk FL, Green C, Lewis RJ, Angus DC, McArthur CJ, Berry S, Derde LPG, Webb SA, Gordon AC. Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2022 Apr 5;327(13):1247-1259. doi: 10.1001/jama.2022.2910."; "35315874"; "Writing Committee for the REMAP-CAP Investigators; Estcourt LJ, Turgeon AF, McQuilten ZK, McVerry BJ, Al-Beidh F, Annane D, Arabi YM, Arnold DM, Beane A, Begin P, van Bentum-Puijk W, Berry LR, Bhimani Z, Birchall JE, Bonten MJM, Bradbury CA, Brunkhorst FM, Buxton M, Callum JL, Chasse M, Cheng AC, Cove ME, Daly J, Derde L, Detry MA, De Jong M, Evans A, Fergusson DA, Fish M, Fitzgerald M, Foley C, Goossens H, Gordon AC, Gosbell IB, Green C, Haniffa R, Harvala H, Higgins AM, Hills TE, Hoad VC, Horvat C, Huang DT, Hudson CL, Ichihara N, Laing E, Lamikanra AA, Lamontagne F, Lawler PR, Linstrum K, Litton E, Lorenzi E, MacLennan S, Marshall J, McAuley DF, McDyer JF, McGlothlin A, McGuinness S, Miflin G, Montgomery S, Mouncey PR, Murthy S, Nichol A, Parke R, Parker JC, Priddee N, Purcell DFJ, Reyes LF, Richardson P, Robitaille N, Rowan KM, Rynne J, Saito H, Santos M, Saunders CT, Serpa Neto A, Seymour CW, Silversides JA, Tinmouth AA, Triulzi DJ, Turner AM, van de Veerdonk F, Walsh TS, Wood EM, Berry S, Lewis RJ, Menon DK, McArthur C, Zarychanski R, Angus DC, Webb SA, Roberts DJ, Shankar-Hari M. Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2021 Nov 2;326(17):1690-1702. doi: 10.1001/jama.2021.18178."; "34606578"; "Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2."; "34473343"; "REMAP-CAP Investigators; ACTIV-4a Investigators; ATTACC Investigators; Goligher EC, Bradbury CA, McVerry BJ, Lawler PR, Berger JS, Gong MN, Carrier M, Reynolds HR, Kumar A, Turgeon AF, Kornblith LZ, Kahn SR, Marshall JC, Kim KS, Houston BL, Derde LPG, Cushman M, Tritschler T, Angus DC, Godoy LC, McQuilten Z, Kirwan BA, Farkouh ME, Brooks MM, Lewis RJ, Berry LR, Lorenzi E, Gordon AC, Ahuja T, Al-Beidh F, Annane D, Arabi YM, Aryal D, Baumann Kreuziger L, Beane A, Bhimani Z, Bihari S, Billett HH, Bond L, Bonten M, Brunkhorst F, Buxton M, Buzgau A, Castellucci LA, Chekuri S, Chen JT, Cheng AC, Chkhikvadze T, Coiffard B, Contreras A, Costantini TW, de Brouwer S, Detry MA, Duggal A, Dzavik V, Effron MB, Eng HF, Escobedo J, Estcourt LJ, Everett BM, Fergusson DA, Fitzgerald M, Fowler RA, Froess JD, Fu Z, Galanaud JP, Galen BT, Gandotra S, Girard TD, Goodman AL, Goossens H, Green C, Greenstein YY, Gross PL, Haniffa R, Hegde SM, Hendrickson CM, Higgins AM, Hindenburg AA, Hope AA, Horowitz JM, Horvat CM, Huang DT, Hudock K, Hunt BJ, Husain M, Hyzy RC, Jacobson JR, Jayakumar D, Keller NM, Khan A, Kim Y, Kindzelski A, King AJ, Knudson MM, Kornblith AE, Kutcher ME, Laffan MA, Lamontagne F, Le Gal G, Leeper CM, Leifer ES, Lim G, Gallego Lima F, Linstrum K, Litton E, Lopez-Sendon J, Lother SA, Marten N, Saud Marinez A, Martinez M, Mateos Garcia E, Mavromichalis S, McAuley DF, McDonald EG, McGlothlin A, McGuinness SP, Middeldorp S, Montgomery SK, Mouncey PR, Murthy S, Nair GB, Nair R, Nichol AD, Nicolau JC, Nunez-Garcia B, Park JJ, Park PK, Parke RL, Parker JC, Parnia S, Paul JD, Pompilio M, Quigley JG, Rosenson RS, Rost NS, Rowan K, Santos FO, Santos M, Santos MO, Satterwhite L, Saunders CT, Schreiber J, Schutgens REG, Seymour CW, Siegal DM, Silva DG Jr, Singhal AB, Slutsky AS, Solvason D, Stanworth SJ, Turner AM, van Bentum-Puijk W, van de Veerdonk FL, van Diepen S, Vazquez-Grande G, Wahid L, Wareham V, Widmer RJ, Wilson JG, Yuriditsky E, Zhong Y, Berry SM, McArthur CJ, Neal MD, Hochman JS, Webb SA, Zarychanski R. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. N Engl J Med. 2021 Aug 26;385(9):777-789. doi: 10.1056/NEJMoa2103417. Epub 2021 Aug 4."; "34351722"; "ATTACC Investigators; ACTIV-4a Investigators; REMAP-CAP Investigators; Lawler PR, Goligher EC, Berger JS, Neal MD, McVerry BJ, Nicolau JC, Gong MN, Carrier M, Rosenson RS, Reynolds HR, Turgeon AF, Escobedo J, Huang DT, Bradbury CA, Houston BL, Kornblith LZ, Kumar A, Kahn SR, Cushman M, McQuilten Z, Slutsky AS, Kim KS, Gordon AC, Kirwan BA, Brooks MM, Higgins AM, Lewis RJ, Lorenzi E, Berry SM, Berry LR, Aday AW, Al-Beidh F, Annane D, Arabi YM, Aryal D, Baumann Kreuziger L, Beane A, Bhimani Z, Bihari S, Billett HH, Bond L, Bonten M, Brunkhorst F, Buxton M, Buzgau A, Castellucci LA, Chekuri S, Chen JT, Cheng AC, Chkhikvadze T, Coiffard B, Costantini TW, de Brouwer S, Derde LPG, Detry MA, Duggal A, Dzavik V, Effron MB, Estcourt LJ, Everett BM, Fergusson DA, Fitzgerald M, Fowler RA, Galanaud JP, Galen BT, Gandotra S, Garcia-Madrona S, Girard TD, Godoy LC, Goodman AL, Goossens H, Green C, Greenstein YY, Gross PL, Hamburg NM, Haniffa R, Hanna G, Hanna N, Hegde SM, Hendrickson CM, Hite RD, Hindenburg AA, Hope AA, Horowitz JM, Horvat CM, Hudock K, Hunt BJ, Husain M, Hyzy RC, Iyer VN, Jacobson JR, Jayakumar D, Keller NM, Khan A, Kim Y, Kindzelski AL, King AJ, Knudson MM, Kornblith AE, Krishnan V, Kutcher ME, Laffan MA, Lamontagne F, Le Gal G, Leeper CM, Leifer ES, Lim G, Lima FG, Linstrum K, Litton E, Lopez-Sendon J, Lopez-Sendon Moreno JL, Lother SA, Malhotra S, Marcos M, Saud Marinez A, Marshall JC, Marten N, Matthay MA, McAuley DF, McDonald EG, McGlothlin A, McGuinness SP, Middeldorp S, Montgomery SK, Moore SC, Morillo Guerrero R, Mouncey PR, Murthy S, Nair GB, Nair R, Nichol AD, Nunez-Garcia B, Pandey A, Park PK, Parke RL, Parker JC, Parnia S, Paul JD, Perez Gonzalez YS, Pompilio M, Prekker ME, Quigley JG, Rost NS, Rowan K, Santos FO, Santos M, Olombrada Santos M, Satterwhite L, Saunders CT, Schutgens REG, Seymour CW, Siegal DM, Silva DG Jr, Shankar-Hari M, Sheehan JP, Singhal AB, Solvason D, Stanworth SJ, Tritschler T, Turner AM, van Bentum-Puijk W, van de Veerdonk FL, van Diepen S, Vazquez-Grande G, Wahid L, Wareham V, Wells BJ, Widmer RJ, Wilson JG, Yuriditsky E, Zampieri FG, Angus DC, McArthur CJ, Webb SA, Farkouh ME, Hochman JS, Zarychanski R. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med. 2021 Aug 26;385(9):790-802. doi: 10.1056/NEJMoa2105911. Epub 2021 Aug 4."; "34351721"; "Arabi YM, Gordon AC, Derde LPG, Nichol AD, Murthy S, Beidh FA, Annane D, Swaidan LA, Beane A, Beasley R, Berry LR, Bhimani Z, Bonten MJM, Bradbury CA, Brunkhorst FM, Buxton M, Buzgau A, Cheng A, De Jong M, Detry MA, Duffy EJ, Estcourt LJ, Fitzgerald M, Fowler R, Girard TD, Goligher EC, Goossens H, Haniffa R, Higgins AM, Hills TE, Horvat CM, Huang DT, King AJ, Lamontagne F, Lawler PR, Lewis R, Linstrum K, Litton E, Lorenzi E, Malakouti S, McAuley DF, McGlothlin A, Mcguinness S, McVerry BJ, Montgomery SK, Morpeth SC, Mouncey PR, Orr K, Parke R, Parker JC, Patanwala AE, Rowan KM, Santos MS, Saunders CT, Seymour CW, Shankar-Hari M, Tong SYC, Turgeon AF, Turner AM, Van de Veerdonk FL, Zarychanski R, Green C, Berry S, Marshall JC, McArthur C, Angus DC, Webb SA; REMAP-CAP Investigators. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Intensive Care Med. 2021 Aug;47(8):867-886. doi: 10.1007/s00134-021-06448-5. Epub 2021 Jul 12."; "34251506"; "REMAP-CAP Investigators; Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, Annane D, Beane A, van Bentum-Puijk W, Berry LR, Bhimani Z, Bonten MJM, Bradbury CA, Brunkhorst FM, Buzgau A, Cheng AC, Detry MA, Duffy EJ, Estcourt LJ, Fitzgerald M, Goossens H, Haniffa R, Higgins AM, Hills TE, Horvat CM, Lamontagne F, Lawler PR, Leavis HL, Linstrum KM, Litton E, Lorenzi E, Marshall JC, Mayr FB, McAuley DF, McGlothlin A, McGuinness SP, McVerry BJ, Montgomery SK, Morpeth SC, Murthy S, Orr K, Parke RL, Parker JC, Patanwala AE, Pettila V, Rademaker E, Santos MS, Saunders CT, Seymour CW, Shankar-Hari M, Sligl WI, Turgeon AF, Turner AM, van de Veerdonk FL, Zarychanski R, Green C, Lewis RJ, Angus DC, McArthur CJ, Berry S, Webb SA, Derde LPG. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021 Apr 22;384(16):1491-1502. doi: 10.1056/NEJMoa2100433. Epub 2021 Feb 25."; "33631065"; "UPMC REMAP-COVID Group, on behalf of the REMAP-CAP Investigators. Implementation of the Randomized Embedded Multifactorial Adaptive Platform for COVID-19 (REMAP-COVID) trial in a US health system-lessons learned and recommendations. Trials. 2021 Jan 28;22(1):100. doi: 10.1186/s13063-020-04997-6. Erratum In: Trials. 2021 Feb 16;22(1):145. doi: 10.1186/s13063-021-05109-8."; "33509275"; "Tume LN, Menzies JC, Ray S, Scholefield BR; UK Paediatric Intensive Care Society Study Group. Research Priorities for U.K. Pediatric Critical Care in 2019: Healthcare Professionals' and Parents' Perspectives. Pediatr Crit Care Med. 2021 May 1;22(5):e294-e301. doi: 10.1097/PCC.0000000000002647."; "33394942"; "Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, van Bentum-Puijk W, Berry L, Bhimani Z, Bonten M, Bradbury C, Brunkhorst F, Buxton M, Buzgau A, Cheng AC, de Jong M, Detry M, Estcourt L, Fitzgerald M, Goossens H, Green C, Haniffa R, Higgins AM, Horvat C, Hullegie SJ, Kruger P, Lamontagne F, Lawler PR, Linstrum K, Litton E, Lorenzi E, Marshall J, McAuley D, McGlothin A, McGuinness S, McVerry B, Montgomery S, Mouncey P, Murthy S, Nichol A, Parke R, Parker J, Rowan K, Sanil A, Santos M, Saunders C, Seymour C, Turner A, van de Veerdonk F, Venkatesh B, Zarychanski R, Berry S, Lewis RJ, McArthur C, Webb SA, Gordon AC; Writing Committee for the REMAP-CAP Investigators; Al-Beidh F, Angus D, Annane D, Arabi Y, van Bentum-Puijk W, Berry S, Beane A, Bhimani Z, Bonten M, Bradbury C, Brunkhorst F, Buxton M, Cheng A, De Jong M, Derde L, Estcourt L, Goossens H, Gordon A, Green C, Haniffa R, Lamontagne F, Lawler P, Litton E, Marshall J, McArthur C, McAuley D, McGuinness S, McVerry B, Montgomery S, Mouncey P, Murthy S, Nichol A, Parke R, Rowan K, Seymour C, Turner A, van de Veerdonk F, Webb S, Zarychanski R, Campbell L, Forbes A, Gattas D, Heritier S, Higgins L, Kruger P, Peake S, Presneill J, Seppelt I, Trapani T, Young P, Bagshaw S, Daneman N, Ferguson N, Misak C, Santos M, Hullegie S, Pletz M, Rohde G, Rowan K, Alexander B, Basile K, Girard T, Horvat C, Huang D, Linstrum K, Vates J, Beasley R, Fowler R, McGloughlin S, Morpeth S, Paterson D, Venkatesh B, Uyeki T, Baillie K, Duffy E, Fowler R, Hills T, Orr K, Patanwala A, Tong S, Netea M, Bihari S, Carrier M, Fergusson D, Goligher E, Haidar G, Hunt B, Kumar A, Laffan M, Lawless P, Lother S, McCallum P, Middeldopr S, McQuilten Z, Neal M, Pasi J, Schutgens R, Stanworth S, Turgeon A, Weissman A, Adhikari N, Anstey M, Brant E, de Man A, Lamonagne F, Masse MH, Udy A, Arnold D, Begin P, Charlewood R, Chasse M, Coyne M, Cooper J, Daly J, Gosbell I, Harvala-Simmonds H, Hills T, MacLennan S, Menon D, McDyer J, Pridee N, Roberts D, Shankar-Hari M, Thomas H, Tinmouth A, Triulzi D, Walsh T, Wood E, Calfee C, O'Kane C, Shyamsundar M, Sinha P, Thompson T, Young I, Bihari S, Hodgson C, Laffey J, McAuley D, Orford N, Neto A, Detry M, Fitzgerald M, Lewis R, McGlothlin A, Sanil A, Saunders C, Berry L, Lorenzi E, Miller E, Singh V, Zammit C, van Bentum Puijk W, Bouwman W, Mangindaan Y, Parker L, Peters S, Rietveld I, Raymakers K, Ganpat R, Brillinger N, Markgraf R, Ainscough K, Brickell K, Anjum A, Lane JB, Richards-Belle A, Saull M, Wiley D, Bion J, Connor J, Gates S, Manax V, van der Poll T, Reynolds J, van Beurden M, Effelaar E, Schotsman J, Boyd C, Harland C, Shearer A, Wren J, Clermont G, Garrard W, Kalchthaler K, King A, Ricketts D, Malakoutis S, Marroquin O, Music E, Quinn K, Cate H, Pearson K, Collins J, Hanson J, Williams P, Jackson S, Asghar A, Dyas S, Sutu M, Murphy S, Williamson D, Mguni N, Potter A, Porter D, Goodwin J, Rook C, Harrison S, Williams H, Campbell H, Lomme K, Williamson J, Sheffield J, van't Hoff W, McCracken P, Young M, Board J, Mart E, Knott C, Smith J, Boschert C, Affleck J, Ramanan M, D'Souza R, Pateman K, Shakih A, Cheung W, Kol M, Wong H, Shah A, Wagh A, Simpson J, Duke G, Chan P, Cartner B, Hunter S, Laver R, Shrestha T, Regli A, Pellicano A, McCullough J, Tallott M, Kumar N, Panwar R, Brinkerhoff G, Koppen C, Cazzola F, Brain M, Mineall S, Fischer R, Biradar V, Soar N, White H, Estensen K, Morrison L, Smith J, Cooper M, Health M, Shehabi Y, Al-Bassam W, Hulley A, Whitehead C, Lowrey J, Gresha R, Walsham J, Meyer J, Harward M, Venz E, Williams P, Kurenda C, Smith K, Smith M, Garcia R, Barge D, Byrne D, Byrne K, Driscoll A, Fortune L, Janin P, Yarad E, Hammond N, Bass F, Ashelford A, Waterson S, Wedd S, McNamara R, Buhr H, Coles J, Schweikert S, Wibrow B, Rauniyar R, Myers E, Fysh E, Dawda A, Mevavala B, Litton E, Ferrier J, Nair P, Buscher H, Reynolds C, Santamaria J, Barbazza L, Homes J, Smith R, Murray L, Brailsford J, Forbes L, Maguire T, Mariappa V, Smith J, Simpson S, Maiden M, Bone A, Horton M, Salerno T, Sterba M, Geng W, Depuydt P, De Waele J, De Bus L, Fierens J, Bracke S, Reeve B, Dechert W, Chasse M, Carrier FM, Boumahni D, Benettaib F, Ghamraoui A, Bellemare D, Cloutier E, Francoeur C, Lamontagne F, D'Aragon F, Carbonneau E, Leblond J, Vazquez-Grande G, Marten N, Wilson M, Albert M, Serri K, Cavayas A, Duplaix M, Williams V, Rochwerg B, Karachi T, Oczkowski S, Centofanti J, Millen T, Duan E, Tsang J, Patterson L, English S, Watpool I, Porteous R, Miezitis S, McIntyre L, Brochard L, Burns K, Sandhu G, Khalid I, Binnie A, Powell E, McMillan A, Luk T, Aref N, Andric Z, Cviljevic S, Dimoti R, Zapalac M, Mirkovic G, Barsic B, Kutlesa M, Kotarski V, Vujaklija Brajkovic A, Babel J, Sever H, Dragija L, Kusan I, Vaara S, Pettila L, Heinonen J, Kuitunen A, Karlsson S, Vahtera A, Kiiski H, Ristimaki S, Azaiz A, Charron C, Godement M, Geri G, Vieillard-Baron A, Pourcine F, Monchi M, Luis D, Mercier R, Sagnier A, Verrier N, Caplin C, Siami S, Aparicio C, Vautier S, Jeblaoui A, Fartoukh M, Courtin L, Labbe V, Leparco C, Muller G, Nay MA, Kamel T, Benzekri D, Jacquier S, Mercier E, Chartier D, Salmon C, Dequin P, Schneider F, Morel G, L'Hotellier S, Badie J, Berdaguer FD, Malfroy S, Mezher C, Bourgoin C, Megarbane B, Voicu S, Deye N, Malissin I, Sutterlin L, Guitton C, Darreau C, Landais M, Chudeau N, Robert A, Moine P, Heming N, Maxime V, Bossard I, Nicholier TB, Colin G, Zinzoni V, Maquigneau N, Finn A, Kress G, Hoff U, Friedrich Hinrichs C, Nee J, Pletz M, Hagel S, Ankert J, Kolanos S, Bloos F, Petros S, Pasieka B, Kunz K, Appelt P, Schutze B, Kluge S, Nierhaus A, Jarczak D, Roedl K, Weismann D, Frey A, Klinikum Neukolln V, Reill L, Distler M, Maselli A, Belteczki J, Magyar I, Fazekas A, Kovacs S, Szoke V, Szigligeti G, Leszkoven J, Collins D, Breen P, Frohlich S, Whelan R, McNicholas B, Scully M, Casey S, Kernan M, Doran P, O'Dywer M, Smyth M, Hayes L, Hoiting O, Peters M, Rengers E, Evers M, Prinssen A, Bosch Ziekenhuis J, Simons K, Rozendaal W, Polderman F, de Jager P, Moviat M, Paling A, Salet A, Rademaker E, Peters AL, de Jonge E, Wigbers J, Guilder E, Butler M, Cowdrey KA, Newby L, Chen Y, Simmonds C, McConnochie R, Ritzema Carter J, Henderson S, Van Der Heyden K, Mehrtens J, Williams T, Kazemi A, Song R, Lai V, Girijadevi D, Everitt R, Russell R, Hacking D, Buehner U, Williams E, Browne T, Grimwade K, Goodson J, Keet O, Callender O, Martynoga R, Trask K, Butler A, Schischka L, Young C, Lesona E, Olatunji S, Robertson Y, Jose N, Amaro dos Santos Catorze T, de Lima Pereira TNA, Neves Pessoa LM, Castro Ferreira RM, Pereira Sousa Bastos JM, Aysel Florescu S, Stanciu D, Zaharia MF, Kosa AG, Codreanu D, Marabi Y, Al Qasim E, Moneer Hagazy M, Al Swaidan L, Arishi H, Munoz-Bermudez R, Marin-Corral J, Salazar Degracia A, Parrilla Gomez F, Mateo Lopez MI, Rodriguez Fernandez J, Carcel Fernandez S, Carmona Flores R, Leon Lopez R, de la Fuente Martos C, Allan A, Polgarova P, Farahi N, McWilliam S, Hawcutt D, Rad L, O'Malley L, Whitbread J, Kelsall O, Wild L, Thrush J, Wood H, Austin K, Donnelly A, Kelly M, O'Kane S, McClintock D, Warnock M, Johnston P, Gallagher LJ, Mc Goldrick C, Mc Master M, Strzelecka A, Jha R, Kalogirou M, Ellis C, Krishnamurthy V, Deelchand V, Silversides J, McGuigan P, Ward K, O'Neill A, Finn S, Phillips B, Mullan D, Oritz-Ruiz de Gordoa L, Thomas M, Sweet K, Grimmer L, Johnson R, Pinnell J, Robinson M, Gledhill L, Wood T, Morgan M, Cole J, Hill H, Davies M, Antcliffe D, Templeton M, Rojo R, Coghlan P, Smee J, Mackay E, Cort J, Whileman A, Spencer T, Spittle N, Kasipandian V, Patel A, Allibone S, Genetu RM, Ramali M, Ghosh A, Bamford P, London E, Cawley K, Faulkner M, Jeffrey H, Smith T, Brewer C, Gregory J, Limb J, Cowton A, O'Brien J, Nikitas N, Wells C, Lankester L, Pulletz M, Williams P, Birch J, Wiseman S, Horton S, Alegria A, Turki S, Elsefi T, Crisp N, Allen L, McCullagh I, Robinson P, Hays C, Babio-Galan M, Stevenson H, Khare D, Pinder M, Selvamoni S, Gopinath A, Pugh R, Menzies D, Mackay C, Allan E, Davies G, Puxty K, McCue C, Cathcart S, Hickey N, Ireland J, Yusuff H, Isgro G, Brightling C, Bourne M, Craner M, Watters M, Prout R, Davies L, Pegler S, Kyeremeh L, Arbane G, Wilson K, Gomm L, Francia F, Brett S, Sousa Arias S, Elin Hall R, Budd J, Small C, Birch J, Collins E, Henning J, Bonner S, Hugill K, Cirstea E, Wilkinson D, Karlikowski M, Sutherland H, Wilhelmsen E, Woods J, North J, Sundaran D, Hollos L, Coburn S, Walsh J, Turns M, Hopkins P, Smith J, Noble H, Depante MT, Clarey E, Laha S, Verlander M, Williams A, Huckle A, Hall A, Cooke J, Gardiner-Hill C, Maloney C, Qureshi H, Flint N, Nicholson S, Southin S, Nicholson A, Borgatta B, Turner-Bone I, Reddy A, Wilding L, Chamara Warnapura L, Agno Sathianathan R, Golden D, Hart C, Jones J, Bannard-Smith J, Henry J, Birchall K, Pomeroy F, Quayle R, Makowski A, Misztal B, Ahmed I, KyereDiabour T, Naiker K, Stewart R, Mwaura E, Mew L, Wren L, Willams F, Innes R, Doble P, Hutter J, Shovelton C, Plumb B, Szakmany T, Hamlyn V, Hawkins N, Lewis S, Dell A, Gopal S, Ganguly S, Smallwood A, Harris N, Metherell S, Lazaro JM, Newman T, Fletcher S, Nortje J, Fottrell-Gould D, Randell G, Zaman M, Elmahi E, Jones A, Hall K, Mills G, Ryalls K, Bowler H, Sall J, Bourne R, Borrill Z, Duncan T, Lamb T, Shaw J, Fox C, Moreno Cuesta J, Xavier K, Purohit D, Elhassan M, Bakthavatsalam D, Rowland M, Hutton P, Bashyal A, Davidson N, Hird C, Chhablani M, Phalod G, Kirkby A, Archer S, Netherton K, Reschreiter H, Camsooksai J, Patch S, Jenkins S, Pogson D, Rose S, Daly Z, Brimfield L, Claridge H, Parekh D, Bergin C, Bates M, Dasgin J, McGhee C, Sim M, Hay SK, Henderson S, Phull MK, Zaidi A, Pogreban T, Rosaroso LP, Harvey D, Lowe B, Meredith M, Ryan L, Hormis A, Walker R, Collier D, Kimpton S, Oakley S, Rooney K, Rodden N, Hughes E, Thomson N, McGlynn D, Walden A, Jacques N, Coles H, Tilney E, Vowell E, Schuster-Bruce M, Pitts S, Miln R, Purandare L, Vamplew L, Spivey M, Bean S, Burt K, Moore L, Day C, Gibson C, Gordon E, Zitter L, Keenan S, Baker E, Cherian S, Cutler S, Roynon-Reed A, Harrington K, Raithatha A, Bauchmuller K, Ahmad N, Grecu I, Trodd D, Martin J, Wrey Brown C, Arias AM, Craven T, Hope D, Singleton J, Clark S, Rae N, Welters I, Hamilton DO, Williams K, Waugh V, Shaw D, Puthucheary Z, Martin T, Santos F, Uddin R, Somerville A, Tatham KC, Jhanji S, Black E, Dela Rosa A, Howle R, Tully R, Drummond A, Dearden J, Philbin J, Munt S, Vuylsteke A, Chan C, Victor S, Matsa R, Gellamucho M, Creagh-Brown B, Tooley J, Montague L, De Beaux F, Bullman L, Kersiake I, Demetriou C, Mitchard S, Ramos L, White K, Donnison P, Johns M, Casey R, Mattocks L, Salisbury S, Dark P, Claxton A, McLachlan D, Slevin K, Lee S, Hulme J, Joseph S, Kinney F, Senya HJ, Oborska A, Kayani A, Hadebe B, Orath Prabakaran R, Nichols L, Thomas M, Worner R, Faulkner B, Gendall E, Hayes K, Hamilton-Davies C, Chan C, Mfuko C, Abbass H, Mandadapu V, Leaver S, Forton D, Patel K, Paramasivam E, Powell M, Gould R, Wilby E, Howcroft C, Banach D, Fernandez de Pinedo Artaraz Z, Cabreros L, White I, Croft M, Holland N, Pereira R, Zaki A, Johnson D, Jackson M, Garrard H, Juhaz V, Roy A, Rostron A, Woods L, Cornell S, Pillai S, Harford R, Rees T, Ivatt H, Sundara Raman A, Davey M, Lee K, Barber R, Chablani M, Brohi F, Jagannathan V, Clark M, Purvis S, Wetherill B, Dushianthan A, Cusack R, de Courcy-Golder K, Smith S, Jackson S, Attwood B, Parsons P, Page V, Zhao XB, Oza D, Rhodes J, Anderson T, Morris S, Xia Le Tai C, Thomas A, Keen A, Digby S, Cowley N, Wild L, Southern D, Reddy H, Campbell A, Watkins C, Smuts S, Touma O, Barnes N, Alexander P, Felton T, Ferguson S, Sellers K, Bradley-Potts J, Yates D, Birkinshaw I, Kell K, Marshall N, Carr-Knott L, Summers C. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA. 2020 Oct 6;324(13):1317-1329. doi: 10.1001/jama.2020.17022."; "32876697"; "Angus DC, Berry S, Lewis RJ, Al-Beidh F, Arabi Y, van Bentum-Puijk W, Bhimani Z, Bonten M, Broglio K, Brunkhorst F, Cheng AC, Chiche JD, De Jong M, Detry M, Goossens H, Gordon A, Green C, Higgins AM, Hullegie SJ, Kruger P, Lamontagne F, Litton E, Marshall J, McGlothlin A, McGuinness S, Mouncey P, Murthy S, Nichol A, O'Neill GK, Parke R, Parker J, Rohde G, Rowan K, Turner A, Young P, Derde L, McArthur C, Webb SA. The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design. Ann Am Thorac Soc. 2020 Jul;17(7):879-891. doi: 10.1513/AnnalsATS.202003-192SD."; "32267771"

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.

Intervention Arm Group : Antibiotic Domain;

Intervention Type : DRUG
Intervention Description : The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.

Intervention Arm Group : Antibiotic Domain;

Intervention Type : DRUG
Intervention Description : The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.

Intervention Arm Group : Antibiotic Domain;

Intervention Type : DRUG
Intervention Description : The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.

Note: this intervention is now closed.

Intervention Arm Group : Antibiotic Domain;

Intervention Type : DRUG
Intervention Description : The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.

Intervention Arm Group : Antibiotic Domain;

Intervention Type : DRUG
Intervention Description : Standard course of macrolide therapy, discontinued between study day 3 and the end of study day 5.

The dosing of and route of administration is not protocolised, the following guidance is provided:

* Initial IV administration of a macrolide is strongly preferred* The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted.* The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted.

Intervention Arm Group : Macrolide Duration Domain;

Intervention Type : DRUG
Intervention Description : Extended course of macrolide therapy discontinued at the end of study day 14 or hospital discharge (whichever occurs first).

The dosing of and route of administration is not protocolised, the following guidance is provided:

* Initial IV administration of a macrolide is strongly preferred* The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted.* The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted.

Intervention Arm Group : Macrolide Duration Domain;

Intervention Type : OTHER
Intervention Description : Patients are not to receive any systemic corticosteroids, including hydrocortisone, to study day 28 or hospital discharge (whichever occurs first).

Intervention Arm Group : Corticosteroid Domain;

Intervention Type : DRUG
Intervention Description : 50mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days.

Note: this intervention is now closed.

Intervention Arm Group : Corticosteroid Domain;

Intervention Type : DRUG
Intervention Description : 50mg IV hydrocortisone every 6 hours while the patient is in septic shock

Intervention Arm Group : Corticosteroid Domain;

Intervention Type : DRUG
Intervention Description : 100mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days.

Note: this intervention was only available to patients with suspected or proven COVID-19 and is now closed.

Intervention Arm Group : Corticosteroid Domain;

Intervention Type : OTHER
Intervention Description : No antiviral agent intended to be active against influenza infection is to be administered

Intervention Arm Group : Influenza Antiviral Domain;

Intervention Type : DRUG
Intervention Description : Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first)

Intervention Arm Group : Influenza Antiviral Domain;

Intervention Type : DRUG
Intervention Description : Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first)

Intervention Arm Group : Influenza Antiviral Domain;

Intervention Type : OTHER
Intervention Description : No antiviral agent intended to be active against SARS-CoV-2 infection is to be administered

Intervention Arm Group : COVID-19 Antiviral Domain;

Intervention Type : DRUG
Intervention Description : Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU.

Note: this intervention is now closed.

Intervention Arm Group : COVID-19 Antiviral Domain;

Intervention Type : DRUG
Intervention Description : Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first).

Note: this intervention is now closed.

Intervention Arm Group : COVID-19 Antiviral Domain;

Intervention Type : DRUG
Intervention Description : Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU.

Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first).

Note: this intervention is now closed.

Intervention Arm Group : COVID-19 Antiviral Domain;

Intervention Type : DRUG
Intervention Description : Ivermectin administered enterally at a dose of 0.2 mg/kg once daily with a maximum daily dose of 24mg/day.

Note: this intervention is now closed.

Intervention Arm Group : COVID-19 Antiviral Domain;

Intervention Type : OTHER
Intervention Description : No immune modulating agent intended to be active against COVID-19 is to be administered.

Note: this intervention is now closed.

Intervention Arm Group : COVID-19 Immune Modulation (2) Domain;COVID-19 Immune Modulation Domain;

Intervention Type : DRUG
Intervention Description : IFN-β1a 10 μg will be administered as an intravenous bolus injection via a central or peripheral line. IFN-β1a will be administered once daily for 6 days or until ICU discharge, whichever occurs first.

Note: this intervention is now closed.

Intervention Arm Group : COVID-19 Immune Modulation Domain;

Intervention Type : DRUG
Intervention Description : A loading dose of 300mg anakinra will be administered as a bolus via central or peripheral line. This is followed by maintenance doses of 100mg of anakinra administered every 6 hours.

In patients with renal impairment, anakinra will be administered on alternate days.

Note: this intervention is now closed.

Intervention Arm Group : COVID-19 Immune Modulation Domain;

Intervention Type : DRUG
Intervention Description : Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg.

Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period.

Note: this intervention is now closed.

Intervention Arm Group : COVID-19 Immune Modulation Domain;

Intervention Type : DRUG
Intervention Description : Sarilumab will be administered as a single dose of 400mg, via IV infusion through peripheral or central line over a one-hour period.

Note: this intervention is now closed.

Intervention Arm Group : COVID-19 Immune Modulation Domain;

Intervention Type : DRUG
Intervention Description : Standard venous thromboprophylaxis that complies with local guidelines or usual practice will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first.

Note: this intervention is now closed.

Intervention Arm Group : Anticoagulation Domain;

Intervention Type : DRUG
Intervention Description : Patients will be administered either low molecular weight heparin (LMWH) or unfractionated heparin (UFH) to achieve systemic anticoagulation. Either agent may be used and the same patient may be switched between UFH and LMWH at the discretion of the treating clinician.

Note: this intervention is now closed.

Intervention Arm Group : Anticoagulation Domain;

Intervention Type : DRUG
Intervention Description : Low dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain.

Intervention Arm Group : Anticoagulation Domain;

Intervention Type : DRUG
Intervention Description : Intermediate dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain.

Intervention Arm Group : Anticoagulation Domain;

Intervention Type : DRUG
Intervention Description : Patients already receiving therapeutic dose anticoagulation at the time of randomisation to this intervention will be administered either unfractionated heparin by IV infusion or low-molecular weight heparin to achieve systemic anticoagulation according to local practice for acute VTE treatment for 14 days following randomisation or until hospital discharge, whichever occurs first.

Note: this intervention is now closed.

Intervention Arm Group : Anticoagulation Domain;

Intervention Type : OTHER
Intervention Description : No immunoglobulin intended to be active against SARS-CoV-2 infection is to be administered.

Intervention Arm Group : Immunoglobulin Domain;

Intervention Type : BIOLOGICAL
Intervention Description : Patients will receive at least one and no more than two units of ABO compatible convalescent plasma within 48 hours of randomisation.

Intervention Arm Group : Immunoglobulin Domain;

Intervention Type : BIOLOGICAL
Intervention Description : Note: this intervention is now closed.

Intervention Arm Group : Immunoglobulin Domain;

Intervention Type : OTHER
Intervention Description : No high dose intravenous vitamin C is to be administered

Note: this intervention is now closed.

Intervention Arm Group : Vitamin C Domain;

Intervention Type : DRUG
Intervention Description : Intravenous Vitamin C 50mg/kg administered every 6 hours for 16 doses

Note: this intervention is now closed.

Intervention Arm Group : Vitamin C Domain;

Intervention Type : OTHER
Intervention Description : No antiplatelet agent or NSAID to be administered.

Note: this intervention is now closed.

Intervention Arm Group : Antiplatelet Domain;

Intervention Type : DRUG
Intervention Description : Aspirin administered at either 75mg or 100mg once per day for 14 days or until hospital discharge, whichever occurs first.

Note: this intervention is now closed.

Intervention Arm Group : Antiplatelet Domain;

Intervention Type : DRUG
Intervention Description : Site-selected P2Y12 inhibitor:

* Clopidogrel: administered 75 mg once per day for 14 days or until hospital discharge, whichever occurs first.* Prasugrel: If patient is aged less than 75 years and measured or estimated weight if 60kg or more, and initial loading dose of prasugrel 60 mg will be administered, followed by maintenance dose of 10 mg per day.* Ticagrelor: administered enterally at 60mg twice daily for 14 days or until hospital discharge, whichever occurs first.

Note: this intervention is now closed.

Intervention Arm Group : Antiplatelet Domain;

Intervention Type : OTHER
Intervention Description : No simvastatin intended to be active against COVID-19 is to be administered

Note: this intervention is now closed.

Intervention Arm Group : Simvastatin Domain;

Intervention Type : DRUG
Intervention Description : Simvastatin 80mg administered once daily via enteral route, while the patient remains in hospital up to 28 days after randomisation

Note: this intervention is now closed.

Intervention Arm Group : Simvastatin Domain;

Intervention Type : DRUG
Intervention Description : Eritoran initiated with a 26.24 mg loading dose (6.56 mg/h IV for 4 hours), followed by a second 13.12 mg loading dose (6.56 mg/h IV for 2 hours) at 12 hours after initiation. Patients will then receive twenty-six 6.56 mg maintenance doses (3.28 mg/h IV for 2 hours) every 12 hours thereafter (total of 14 days). Dosing will be stopped if the patient is discharged from hospital

Note: this intervention is now closed.

Intervention Arm Group : COVID-19 Immune Modulation (2) Domain;

Intervention Type : DRUG
Intervention Description : Apremilast administered 30mg twice daily for 14 days or until hospital discharge, whichever occurs first.

Note: this intervention is now closed.

Intervention Arm Group : COVID-19 Immune Modulation (2) Domain;

Intervention Type : PROCEDURE
Intervention Description : Clinician-preferred ventilation strategy, including mode of ventilation and all ventilatory parameters

Intervention Arm Group : Mechanical Ventilation Domain;

Intervention Type : PROCEDURE
Intervention Description : Invasive mechanical ventilation strategy delivered as outlined in relevant protocol documents for this domain.

Intervention Arm Group : Mechanical Ventilation Domain;

Intervention Type : OTHER
Intervention Description : No RAS inhibitor (i.e. no ACEi or ARB) is to be administered up to the end of study day 10.

Note: this intervention is now closed.

Intervention Arm Group : ACE2 RAS Domain;

Intervention Type : DRUG
Intervention Description : Site-preferred ACEi agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first.

Note: this intervention is now closed.

Intervention Arm Group : ACE2 RAS Domain;

Intervention Type : DRUG
Intervention Description : Site-preferred ARB agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first.

Note: this intervention is now closed.

Intervention Arm Group : ACE2 RAS Domain;

Intervention Type : DRUG
Intervention Description : Site-preferred ARB agent administered in combination with DMX-200 for 10 days or until hospital discharge, whichever occurs first.

ARB administered as directed by the treating clinician. DMX-200 administered enterally at a dose of 120mg twice daily.

Note: this intervention is now closed.

Intervention Arm Group : ACE2 RAS Domain;

Intervention Type : OTHER
Intervention Description : No cysteamine to be administered until the end of study day 10 or hospital discharge, whichever occurs first.

Note: this intervention is now closed.

Intervention Arm Group : Cysteamine Domain;

Intervention Type : DRUG
Intervention Description : Cysteamine administered every 8 hours at a dose of 5 mg/kg estimated or measured body weight (maximum dose of 500mg), for ten days or until ICU discharge, whichever occurs first.

Note: this intervention is now closed.

Intervention Arm Group : Cysteamine Domain;

Intervention Type : DRUG
Intervention Description : 6 mg of IV or enteral dexamethasone will be administered daily for up to 10 days while in hospital.

Intervention Arm Group : Corticosteroid Domain;

Intervention Type : DRUG
Intervention Description : Baloxavir marboxil administered on days 1 and 4 post-randomisation.

Intervention Arm Group : Influenza Antiviral Domain;

Intervention Type : DRUG
Intervention Description : Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation.

Intervention Arm Group : Influenza Antiviral Domain;

Intervention Type : DRUG
Intervention Description : Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation.

Intervention Arm Group : Influenza Antiviral Domain;

Intervention Type : OTHER
Intervention Description : No endothelial modulator (imatinib or another tyrosine kinase inhibitor targeting the same pathway as imatinib) is to be administered.

Intervention Arm Group : Endothelial Domain;

Intervention Type : DRUG
Intervention Description : Enteral imatinib will be administered as a single 800mg loading dose (study day 1) followed by 400mg daily until study day 14 or discharge.

Intervention Arm Group : Endothelial Domain;

Intervention Type : OTHER
Intervention Description : No immune modulating agent intended to be active against influenza is to be administered.

Intervention Arm Group : Influenza Immune Modulation;

Intervention Type : DRUG
Intervention Description : Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg. In children weighing less than 30kg, tocilizumab dose will be 12mg/kg.

Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period.

Intervention Arm Group : Influenza Immune Modulation;

Intervention Type : DRUG
Intervention Description : Baricitinib will be administered at a dose that is determined by age and renal function, for up to 10 days or hospital discharge (whichever occurs first).

Intervention Arm Group : Influenza Immune Modulation;

Intervention Type : OTHER
Intervention Description : No antiviral agent intended to be active against SARS-CoV-2 infection is to be administered

Intervention Arm Group : COVID-19 Antiviral (II) Domain;

Intervention Type : DRUG
Intervention Description : Nirmatrelvir-ritonavir will be administered at a dose that is dependent on renal function, for five days.

Intervention Arm Group : COVID-19 Antiviral (II) Domain;

Intervention Type : DRUG
Intervention Description : Remdesivir is administered at 200 mg on day one followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first.

Intervention Arm Group : COVID-19 Antiviral (II) Domain;

Intervention Type : DRUG
Intervention Description : Nirmatrelvir-ritonavir will be administered at a dose that is dependent on renal function, for five days. Remdesivir is administered at 200 mg on day one followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first.

Intervention Arm Group : COVID-19 Antiviral (II) Domain;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Dorset County Hospital
    Dorchester
    DT1 2JY
  • Ulster Hospital
    Belfast
    BT16 1RH
  • Warwick Hospital
    Warwick
    CV34 5BW
  • University College London Hospital
    London
    NW1 2BU
  • Leighton Hospital
    Crewe
    CW1 4QJ
  • Homerton Hospital
    London
    E9 6SR
  • Sandwell General Hospital
    West Bromwich
    B71 4HJ
  • St. James University Hospital
    Leeds
    LS9 7TF
  • Fairfield General Hospital
    Bury
    BL9 7TD
  • Leicester Royal Infirmary
    Leicester
    England
    LE1 5WW
  • Aberdeen Royal Infirmary
    Aberdeen
    Scotland
    AB25 2ZN
  • Royal Bournemouth Hospital
    Bournemouth
    England
    BH7 7DW
  • Royal Liverpool University Hospital
    Liverpool
    England
    L7 8XP
  • George Eliot Hospital
    Nuneaton
    England
    CV10 7DJ
  • Southampton General Hospital
    Southampton
    England
    SO16 6YD
  • Royal Hampshire County Hospital
    Winchester
    England
    SO22 5DG
  • Guy's Hospital
    London
    England
    SE1 9RT
  • Maidstone Hospital
    Maidstone
    England
    ME16 9QQ
  • Belfast City Hospital
    Belfast
    Northern Ireland
    BT9 7AB
  • Great Western Hospital
    Swindon
    England
    SN3 6BB
  • Wythenshawe Hospital
    Manchester
    England
    M23 9LT
  • John Radcliffe Hospital
    Oxford
    England
    OX3 9DU
  • Queen Alexandra Hospital
    Portsmouth
    England
    PO6 3LY
  • Musgrove Park Hospital
    Taunton
    England
    TA1 5DA
  • Ninewells Hospital
    Dundee
    Scotland
    DD1 9SY
  • Wrexham Maelor Hospital
    Wrexham
    Wales
    LL13 7TD
  • Russells Hall Hospital
    Dudley
    England
    DY1 2HQ
  • Charing Cross Hospital
    London
    England
    W6 8RF
  • Derriford Hospital
    Plymouth
    England
    PL6 8DH
  • South Tyneside District Hospital
    South Shields
    England
    NE34 0PL
  • Royal Sussex County Hospital
    Brighton
    England
    BN2 5BE
  • Ipswich Hospital
    Ipswich
    England
    IP4 5PD
  • Manchester Royal Infirmary
    Manchester
    England
    M13 9WL
  • Northampton General Hospital
    Northampton
    England
    NN1 5BD
  • Sunderland Royal Hospital
    Sunderland
    England
    SR4 7TP
  • West Cumberland Hospital
    Whitehaven
    England
    CA28 8JG
  • Royal Berkshire Hospital
    Reading
    England
    RG1 5AN
  • Morriston Hospital
    Swansea
    Wales
    SA6 6NL
  • Norfolk and Norwich University Hospital
    Norwich
    England
    NR4 7UY
  • King's College Hospital
    London
    England
    SE5 9RS
  • Royal Cornwall Hospital
    Truro
    England
    TR1 3LJ
  • Royal Free Hospital
    London
    England
    NW3 2QG
  • Royal Hallamshire Hospital
    Sheffield
    England
    S10 2JF
  • Royal Stoke University Hospital
    Stoke-on-Trent
    England
    ST4 6QG
  • Royal Infirmary of Edinburgh
    Edinburgh
    Scotland
    EH16 4SA
  • Royal Marsden Hospital
    London
    England
    SW3 6JJ
  • Northwick Park Hospital
    Harrow
    England
    HA1 3UJ
  • Lincoln County Hospital
    Lincoln
    England
    LN2 5QY
  • Torbay Hospital
    Torquay
    England
    TQ2 7AA
  • Chesterfield Royal Hospital
    Chesterfield
    England
    S44 5BL
  • Countess of Chester Hospital
    Chester
    England
    CH2 1UL
  • Salisbury District Hospital
    Salisbury
    England
    SP2 8BJ
  • Arrowe Park Hospital
    Wirral
    England
    CH49 5PE
  • Glenfield Hospital
    Leicester
    England
    LE3 9QP
  • Whipps Cross Hospital
    London
    England
    E11 1NR
  • Royal Preston Hospital
    Preston
    England
    PR2 9HT
  • Glan Clwyd Hospital
    Bodelwyddan
    Wales
    LL18 5UJ
  • Southmead Hospital
    Bristol
    England
    BS10 5NB
  • Stepping Hill Hospital
    Stockport
    England
    SK2 7JE
  • Gloucester Royal Hospital
    Gloucester
    GL1 3NN
  • Royal Brompton Hospital
    London
    England
    SW3 6NP
  • University Hospital of North Tees
    Stockton-on-Tees
    England
    TS19 8PE
  • Royal Victoria Hospital Belfast
    Belfast
    Northern Ireland
    BT12 6BA
  • Princess of Wales Hospital
    Bridgend
    Wales
    CF31 1RQ
  • Royal Oldham Hospital
    Oldham
    England
    Ol1 2JH
  • Hammersmith Hospital
    London
    England
    W12 0HS
  • Medway Maritime Hospital
    Gillingham
    England
    ME7 5NY
  • Basildon Hospital
    Basildon
    England
    SS16 5NL
  • Basingstoke and North Hampshire Hospital
    Basingstoke
    England
    RG24 9NA
  • Royal United Hospital, Bath
    Bath
    England
    BA1 3NG
  • Queen Elizabeth Hospital Birmingham
    Birmingham
    England
    B15 2TH
  • Birmingham City Hospital
    Birmingham
    England
    B18 7QH
  • Queen's Hospital, Burton
    Burton on Trent
    England
    DE13 0RB
  • Royal Papworth Hospital
    Cambridge
    England
    CB2 0AY
  • Addenbrookes Hospital
    Cambridge
    England
    CB2 0QQ
  • Colchester Hospital
    Colchester
    England
    CO4 5JL
  • University Hospital Coventry
    Coventry
    England
    CV2 2DX
  • Darlington Memorial Hospital
    Darlington
    England
    DL3 6HX
  • Darent Valley Hospital
    Dartford
    England
    DA2 8DA
  • Frimley Park Hospital
    Frimley
    England
    GU16 7 UJ
  • Royal Surrey County Hospital
    Guildford
    England
    GU2 7XX
  • Hereford County Hospital
    Hereford
    England
    HR1 2ER
  • Barnet Hospital
    High Barnet
    England
    EN5 3DJ
  • King George Hospital
    Ilford
    England
    IG3 8YB
  • Kettering Hospital
    Kettering
    England
    NN16 8UZ
  • Liverpool Heart and Chest Hospital
    Liverpool
    England
    L14 3PE
  • Alder Hey Hospital
    Liverpool
    England
    L14 5AB
  • University Hospital Aintree
    Liverpool
    England
    L9 7AL
  • Croydon University Hospital
    London
    England
    CR7 7YE
  • Royal London Hospital
    London
    England
    E1 1FR
  • St Mary's Hospital
    London
    England
    W2 1NY
  • Luton and Dunstable University Hospital
    Luton
    England
    LU4 0DZ
  • The Christie Hospital
    Manchester
    England
    M20 4BX
  • The James Cook University Hospital
    Middlesbrough
    England
    TS4 3BW
  • Milton Keynes University Hospital
    Milton Keynes
    England
    MK6 5LD
  • Royal Victoria Infirmary, Newcastle
    Newcastle
    England
    NE1 4LP
  • Newcastle Freeman Hospital
    Newcastle
    England
    NE7 7DN
  • City Hospital Nottingham
    Nottingham
    England
    NG5 1PB
  • Queen's Medical Centre - Nottingham University Hospitals NHS Trust
    Nottingham
    England
    NG7 2UH
  • Princess Royal University Hospital
    Orpington
    England
    BR6 8ND
  • Poole Hospital NHS Foundation Trust
    Poole
    England
    BH15 2JB
  • Whiston Hospital
    Prescot
    England
    L35 5DR
  • Alexandra Hospital, Redditch
    Redditch
    England
    B98 7UB
  • Queen's Hospital Romford
    Romford
    England
    RM7 0AG
  • Salford Royal Hospital
    Salford
    England
    M6 8HD
  • Northern General Hospital
    Sheffield
    England
    S5 7AU
  • Wexham Park Hospital
    Slough
    England
    SL2 4HL
  • King's Mill Hospital
    Sutton In Ashfield
    England
    NG17 4JL
  • Western General Hospital
    Swindon
    England
    SN3 6BB
  • Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust
    Tunbridge Wells
    England
    TN2 4QJ
  • Harefield Hospital
    Uxbridge
    England
    UB9 6JH
  • Watford General Hospital
    Watford
    England
    WD18 0HB
  • Royal Albert Edward Infirmary
    Wigan
    England
    WN1 2NN
  • Antrim Area Hospital
    Antrim
    Northern Ireland
    BT41 2RL
  • Mater Hospital
    Belfast
    Northern Ireland
    BT14 6AB
  • Altnagelvin Hospital
    Derry
    Northern Ireland
    BT47 6SB
  • Glasgow Royal Infirmary
    Glasgow
    Scotland
    G4 0SF
  • Queen Elizabeth University Hospital, Glasgow
    Glasgow
    Scotland
    G51 4TF
  • Neville Hall Hospital
    Abergavenny
    Wales
    NP7 7EG
  • Glangwilli Hospital
    Carmarthen
    Wales
    SA31 2AF
  • Grange University Hospital
    Cwmbran
    Wales
    NP44 8YN
  • Royal Gwent Hospital
    Newport
    Wales
    NP20 2UB
  • Royal Glamorgan Hospital
    Pontyclun
    Wales
    CF72 8XR
  • Royal Alexandra Hospital
    Paisley
    Scotland
    PA2 9PN
  • Leeds General Infirmary
    Leeds
    England
    LS9 7TF
  • Bristol Royal Childrens Hospital
    Bristol
    BS2 8BJ
  • St Bartholomew's Hospital
    London
    England
    EC1A 7BE
  • St George's University Hospital
    London
    England
    SW17 0QT
  • Royal Blackburn Teaching Hospital
    Blackburn
    England
    BB2 3HH
  • Pilgrim Hospital ULHT
    Boston
    England
    PE21 9QS
  • Bristol Royal Infirmary
    Bristol
    England
    BS2 8EX
  • North Cumberland Infirmary
    Carlisle
    England
    CA2 7HY
  • St Peter's Hospital
    Chertsey
    England
    KT16 0P
  • Queen Elizabeth Hospital Gateshead
    Gateshead
    England
    NE9 6SX
  • James Paget University Hospital
    Great Yarmouth
    England
    NR31 6LA
  • Huddersfield Royal Infirmary
    Huddersfield
    England
    HD3 3EA
  • Newham University Hospital
    London
    England
    E13 8SL
  • North Middlesex University Hospital
    London
    England
    N18 1QX
  • St Thomas Hospital
    London
    England
    SE1 7EH
  • Queen Elizabeth Hospital, Woolwich
    London
    England
    SE18 4QH
  • North Manchester General Hospital
    Manchester
    England
    M8 5RB
  • Rotherham Hospital
    Rotherham
    England
    S60 2UD
  • Southend Hospital
    Westcliff-on-Sea
    England
    ISS0 0RY
  • New Cross Hospital Wolverhampton
    Wolverhampton
    England
    WV10 0QP
  • Worcestershire Royal Hospital
    Worcester
    England
    WR5 1DD
  • York Teaching Hospital
    York
    England
    Y031 8HE
  • Cardiff and Vale University Hospital Wales
    Cardiff
    Wales
    CF14 4XW
  • The Princess Royal Hospital Haywards Heath
    Haywards Heath
    RH16 4EX
  • Queen Elizabeth and Queen Mother Hospital
    Margate
    CT9 4AN
  • Newcastle Royal Victoria Infirmary (Paediatrics)
    Newcastle Upon Tyne
    NE1 4LP
  • Royal Devon and Exeter Hospital
    Exeter
    England
    Ex2 5DW
  • Chelsea and Westminster Hospital
    London
    SW10 9NH
  • North Tyneside General Hospital
    North Shields
    Ne29 8NH

Unfortunately, this study is not recruiting public volunteers at this time. This is because the research isn’t ready for volunteers yet or the researchers are directly identifying volunteers in certain areas or hospitals. Please do not contact the research team as they will not be able to respond. For more information about research in general, visit the Be Part of Research homepage.  


The study is sponsored by UMC Utrecht and is in collaboration with Australian and New Zealand Intensive Care Research Centre; Medical Research Institute of New Zealand; Unity Health; Berry Consultants; Global Coalition for Adaptive Research; University of Pittsburgh Medical Center; Intensive Care National Audit & Research Centre; St. Marianna University School of Medicine; Nat Intensive Care Surveillance - MORU; National University Hospital, Singapore.




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?

Read full details for Trial ID: NCT02735707
Last updated 10 July 2024

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.